Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Samuel F Hunter, Jas Bindra, Ishveen Chopra, John Niewoehner, Mary P Panaccio & George J Wan. (2021) Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis. ClinicoEconomics and Outcomes Research 13, pages 883-892.
Read now
Read now
Surachat Ngorsuraches & Nabin Poudel. (2021) Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 183-195.
Read now
Read now
Hamid Reza Nakhaipour, Umakanth Vudumula, Vivek Khurana, Guillaume Sébire, Jean K. Mah, Daniela Pohl, Robyn Schecter & Nicholas Adlard. (2020) Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada. Journal of Medical Economics 23:12, pages 1525-1533.
Read now
Read now
Nikolaos Kotsopoulos, Mark P. Connolly, Thibaut Dort & Andrius Kavaliunas. (2020) The fiscal consequences of public health investments in disease-modifying therapies for the treatment of multiple sclerosis in Sweden. Journal of Medical Economics 23:8, pages 831-837.
Read now
Read now
Evelyn Walter, Thomas Berger, Barbara Bajer-Kornek & Florian Deisenhammer. (2019) Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria. Journal of Medical Economics 22:3, pages 226-237.
Read now
Read now
Hongbo Yang, Emilie Duchesneau, Rebekah Foster, Annie Guerin, Esprit Ma & Nina P. Thomas. (2017) Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. Journal of Medical Economics 20:10, pages 1056-1065.
Read now
Read now
Articles from other publishers (18)
Virender Bhan, Fraser Clift, Moogeh Baharnoori, Kimberly Thomas, Barkha P Patel, François Blanchette, Nicholas Adlard, Umakanth Vudumula, Kapil Gudala, Nikkita Dutta, Daniel Grima, Soukaïna Mouallif & Fatine Farhane. (2023) Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. Journal of Comparative Effectiveness Research 12:9.
Crossref
Crossref
Avery McKennaGrace A LinMelanie D WhittingtonDmitriy NikitinSerina Herron-SmithJonathan D CampbellFoluso AgboolaSteven D Pearson. (2023) Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value. Journal of Managed Care & Specialty Pharmacy 29:7, pages 857-861.
Crossref
Crossref
B. Rodríguez-Sánchez, S. Daugbjerg, L. M. Peña-Longobardo, J. Oliva-Moreno, I. Aranda-Reneo, A. Cicchetti & J. López-Bastida. (2022) Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease. The European Journal of Health Economics 24:2, pages 247-277.
Crossref
Crossref
Y. Seitaridou, M. Dimitrova, T. Chamova, M. Kamusheva & P. Panayotov. (2022) Cost-Effectiveness of Multiple Sclerosis Therapies – A Literature Review. Acta Medica Bulgarica 49:4, pages 69-80.
Crossref
Crossref
Moogeh Baharnoori, Virender Bhan, Fraser Clift, Kimberly Thomas, Soukaïna Mouallif, Nicholas Adlard, Philip Cooney, François Blanchette, Barkha P. Patel & Daniel Grima. (2022) Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada. PharmacoEconomics - Open 6:6, pages 859-870.
Crossref
Crossref
Anggie Wiyani, Lohit Badgujar, Vivek Khurana & Nicholas Adlard. (2021) How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy 10:2, pages 557-583.
Crossref
Crossref
S. Simeonova & R. Nikolova. (2021) Significance of the Dominant Psychological and Physiological Aspects of the Occupational Stress Models. Acta Medica Bulgarica 48:4, pages 33-42.
Crossref
Crossref
Nadine Schur, Kapil Gudala, Umakanth Vudumula, Sreelatha Vadapalle, Arjun Bhadhuri, Alain Casanova, Nicholas Adlard & Matthias Schwenkglenks. (2021) Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland. PharmacoEconomics 39:5, pages 563-577.
Crossref
Crossref
Ingrid E. H. Kremer, Mickael Hiligsmann, Josh Carlson, Marita Zimmermann, Peter J. Jongen, Silvia M. A. A. Evers, Svenja Petersohn, Xavier G. L. V. Pouwels & Nick Bansback. (2020) Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. Medical Decision Making 40:8, pages 1003-1019.
Crossref
Crossref
Le H. HuaCarrie M. HershPeter MortenJeanette KuselFeng LinJulie CaveStefan VargaVivian HerreraJohn J. Ko. (2019) The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis. Journal of Managed Care & Specialty Pharmacy 25:4, pages 490-498.
Crossref
Crossref
Yan Xu, Ningying Mao, Viktor Chirikov, Fen Du, Yu-Chen Yeh, Li Liu, Ruiqi Liu & Xin Gao. (2019) Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China. Clinical Drug Investigation 39:3, pages 331-340.
Crossref
Crossref
Viktor Chirikov, Ingrid Ma, Namita Joshi, Dipen Patel, Alden Smith, Cindy Giambrone, Noelle Cornelio & Lobat Hashemi. (2019) Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States. Value in Health 22:2, pages 168-176.
Crossref
Crossref
Sen Lin. 2019. The Science and Regulations of Naturally Derived Complex Drugs. The Science and Regulations of Naturally Derived Complex Drugs
271
295
.
Luis Hernandez, Malinda O’Donnell & Maarten Postma. (2018) Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. PharmacoEconomics 36:10, pages 1223-1252.
Crossref
Crossref
Ricardo Constantino Ginestal López. (2018) Eficiencia de las nuevas opciones terapéuticas para el tratamiento de la esclerosis múltiple; una revisión farmacoeconómica. PharmacoEconomics Spanish Research Articles 15:1-4, pages 3-12.
Crossref
Crossref
Andrew Chan, Gary Cutter, Robert J Fox, James Xiao, James B Lewin & Michael R Edwards. (2017) Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research 6:4, pages 313-323.
Crossref
Crossref
Yang Yao, Weimin Miao, Zhijia Liu, Wei Han, Kaibin Shi, Yi Shen, Handong Li, Qiang Liu, Ying Fu, DeRen Huang & Fu-Dong Shi. (2016) Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice. Translational Stroke Research 7:6, pages 535-547.
Crossref
Crossref
Ralf A. Linker & Aiden Haghikia. (2016) Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy. Therapeutic Advances in Chronic Disease 7:4, pages 198-207.
Crossref
Crossref